Tasly Pharmaceutical Hits Day High with 4.42% Surge in Stock Price

Tasly Pharmaceutical Group Co., Ltd. has experienced a notable increase of 4.42% on July 20, 2026, reaching an intraday high of CNY 16.24. This performance stands in contrast to the China Shanghai Composite, which saw a modest gain of 0.85% on the same day. Over the past week, Tasly has shown a robust performance with an 11.68% increase, while the broader index declined by 3.0%. In terms of longer-term performance, Tasly's stock has risen by 6.57% year-to-date, outperforming the China Shanghai Composite, which has dropped by 4.35%. However, the company has faced challenges in the past year, with a slight decline of 0.86% compared to the index's gain of 7.41%. Key financial metrics for Tasly include a market capitalization of CNY 20,981 million and a price-to-earnings ratio of 22.00. The company also offers a dividend yield of 2.22% and has a return on equity of 7.63%. Despite recent gains, Tasly's long-term growth has been hindered by declining net sales and operating profit over the past five years.